Gamida Cell Gears Up For Omidubicel Submission
Seeks Partners For Bone Marrow Transplant Cell Therapy
Executive Summary
With funding drying up for biotechs as sentiment continues to turn against the sector, Israel-headquartered Gamida Cell is cutting jobs and putting out feelers for potential partners to take its promising cell therapy to market.
You may also be interested in...
Five Potential Blockbuster Oncology Approvals To Look Out For In 2023
With help from Biomedtracker, Scrip takes a look at five drug candidates in oncology poised to win a US thumbs up next year. These novel assets, including three bispecific antibodies, could attract blockbuster figures, according to industry observers.
Keeping Track Of Rolling Submissions: Gamida Cell, Roche, Lilly And Reata Are Latest To Use Fast Track
Applications are underway for omidubicel, mosenutuzumab, pirtobrutinib and omaveloxolone.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.